CasZyme

Executive Summary

CasZyme is a European biotechnology company founded in 2017 that specializes in CRISPR technology, offering customized solutions for healthcare, agriculture, and industrial biotech. With a flexible platform and deep scientific expertise, CasZyme partners with clients to bring market-ready products to life. The company is well-positioned to capitalize on the growing demand for gene editing tools, particularly in therapeutic and agricultural applications. Despite being privately held with undisclosed funding and valuation, CasZyme's focus on partnership-driven innovation suggests potential for steady growth. The company's location in Vilnius, Lithuania, provides access to EU research networks and talent. While no specific pipelines or financial details are public, CasZyme's business model as a trusted innovator and partner could lead to strategic collaborations and productization of its CRISPR platform in the near to medium term.

Upcoming Catalysts (preview)

• H2 2026Announcement of strategic partnership with a major pharmaceutical company for therapeutic CRISPR applications40% success
• Q4 2026Launch of a novel CRISPR platform for agricultural gene editing, targeting crop resilience50% success
• Q3 2026Completion of Series B funding round to scale operations and expand R&D60% success